Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Hupperts

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Plos One|June 9, 2016
Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-UpAnne-Hilde Muris, Joost Smolders, Linda Rolf, et al.
Journal of Neuroimmunology|July 19, 2021
Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patientsMax Mimpen, Jan Damoiseaux, William van Doorn, et al.
Neurology|October 10, 2019
Randomized trial of daily high-dose vitamin D<sub>3</sub> in patients with RRMS receiving subcutaneous interferon β-1aRaymond Hupperts, Joost Smolders, Reinhold Vieth, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2015
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trialRaymond Hupperts, Jan Lycke, Christine Short, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2019
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trialMelissa Cambron, Jop Mostert, Marie D'Hooghe, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 22, 2017
Exploring the effect of vitamin D<sub>3</sub> supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosisLinda Rolf, Anne-Hilde Muris, Amandine Mathias, et al.
Patient Preference and Adherence|June 17, 2016
Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplinesPeter Joseph Jongen, Wim A Lemmens, Raymond Hupperts, et al.
Journal of Neurochemistry|June 11, 2013
Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosisMyrthe Rouwette, Jean-Paul Noben, Jack Van Horssen, et al.
Journal of the Neurological Sciences|May 31, 2011
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trialJoost Smolders, Raymond Hupperts, Frederik Barkhof, et al.
Neurology and Therapy|March 10, 2026
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS StudyBruno Brochet, Dawn Langdon, Eva Kubala Havrdova, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Plos One|June 9, 2016
Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-UpAnne-Hilde Muris, Joost Smolders, Linda Rolf, et al.
Journal of Neuroimmunology|July 19, 2021
Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patientsMax Mimpen, Jan Damoiseaux, William van Doorn, et al.
Neurology|October 10, 2019
Randomized trial of daily high-dose vitamin D<sub>3</sub> in patients with RRMS receiving subcutaneous interferon β-1aRaymond Hupperts, Joost Smolders, Reinhold Vieth, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2015
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trialRaymond Hupperts, Jan Lycke, Christine Short, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2019
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trialMelissa Cambron, Jop Mostert, Marie D'Hooghe, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 22, 2017
Exploring the effect of vitamin D<sub>3</sub> supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosisLinda Rolf, Anne-Hilde Muris, Amandine Mathias, et al.
Patient Preference and Adherence|June 17, 2016
Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplinesPeter Joseph Jongen, Wim A Lemmens, Raymond Hupperts, et al.
Journal of Neurochemistry|June 11, 2013
Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosisMyrthe Rouwette, Jean-Paul Noben, Jack Van Horssen, et al.
Journal of the Neurological Sciences|May 31, 2011
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trialJoost Smolders, Raymond Hupperts, Frederik Barkhof, et al.
Neurology and Therapy|March 10, 2026
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS StudyBruno Brochet, Dawn Langdon, Eva Kubala Havrdova, et al.
Pageof 12